Alexander Hardy is the President and CEO of BioMarin Pharmaceuticals, a leader in biotechnology, since December 1, 2023. He has over 30 years of experience in the global healthcare and biotechnology sectors, most recently serving as CEO of Genentech, a...

Alexander Hardy is the President and CEO of BioMarin Pharmaceuticals, a leader in biotechnology, since December 1, 2023. He has over 30 years of experience in the global healthcare and biotechnology sectors, most recently serving as CEO of Genentech, a Roche company. Hardy's background includes positions like Head of Global Product Strategy and Head of Asia Pacific at Roche Pharma. He's well-educated, holding a BA from the University of Cambridge and an MBA from the University of Michigan. Under his leadership, BioMarin continues to focus on innovative therapies for serious diseases, aligning with Hardy's extensive knowledge in managing biotech organizations. In his first year at BioMarin, he received a total compensation of approximately $1.848 million, which included a significant signing bonus as he transitioned from Genentech. His experience suggests a strong potential to enhance BioMarin's pipeline and drive future growth.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other BioMarin Pharmaceuticals CEOs

B

Alexander Hardy

CEO of BioMarin Pharmaceuticals

Education

B.A. from the University of Cambridge; M.B.A. from the University of Michigan’s Ross School of Business

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of BioMarin Pharmaceuticals for

1 year 4 months (Dec 2023 - Present)

Previous Experience

Chief Executive Officer of Genentech, Inc.; Head of Global Product Strategy at Roche; various leadership roles at Genentech and Novartis.

Rivals

Competitors/colleagues of Alexander Hardy

Holdings

See how much did Alexander Hardy make over time.

Alexander Hardy has been involved in significant stock trading activities that reflect his investment in the company. His insider trading history shows a peak net worth tied to his holdings that reached nearly $39 million back in December 2019. Since...

Alexander Hardy has been involved in significant stock trading activities that reflect his investment in the company. His insider trading history shows a peak net worth tied to his holdings that reached nearly $39 million back in December 2019. Since then, his wealth has seen fluctuations, dipping to around $28.80 million in October 2023 and slightly increasing to about $30.29 million as of September 2023. His vested stock options and restricted stock units are designed to motivate and align his performance with shareholders, and while he just started his role at BioMarin, his past indicates he has been vested in making impactful long-term gains. His holdings are essential not just in terms of financial stability but also for ensuring that his interests align closely with those of the shareholders. This history of stock trading showcases his commitment to the company and industry, utilizing his insights to navigate the complexities of the biotechnology market.

Insider Trading

See recent insider trades of Alexander Hardy.

BMRN

44,360 shares

BMRN

Mar 14, 2025

Received

BMRN

$16.80K

BMRN at $56.01/share

Nov 29, 2024

Received

BMRN

32,780 shares

BMRN

Mar 15, 2024

Received

BMRN

115,371 shares

BMRN

Dec 1, 2023

Received

Compensation History

See how much did Alexander Hardy make over time.

In 2023, Alexander Hardy received a total compensation of about $1.8 million, which included a base salary of $1.05 million and a signing bonus of $900,000 to compensate for his transition from Genentech. Although no stock was vested during his first month as CEO, he was granted restricted stock units (RSUs) worth approximately $10.7 million, designed to vest over the next few years. Hardy's compensation package reflects the company's focus on aligning executive pay with performance and shareholder interests. Moving into 2024, it is expected that a substantial portion of his pay will be performance-based, indicating that his goals are heavily tied to the company's success and stock performance. This pay strategy emphasizes BioMarin's pay-for-performance philosophy while aiming to attract top executives.

Year

2023

Total Compensation

$1.99M

Salary

$1.05M

Board Justification

The compensation philosophy aims to attract and retain executive talent necessary to advance the business and increase stockholder value, with a strong emphasis on performance-based compensation.

Bonus

$900.00K

Board Justification

Signing bonus as a 'make whole' component for potential forfeited bonus at his prior employer due to the timing of the transition late in the year.

Other

$40.22K

Board Justification

Includes reimbursement of legal expenses in connection with the review of his employment agreement and imputed income associated with life insurance premium payments.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as Mr. Hardy was appointed CEO effective December 1, 2023, and did not receive any performance-based equity awards for 2023.

Performance Metrics

Performance metrics for 2023 were not applicable to Mr. Hardy as he was appointed CEO on December 1, 2023.

Other BioMarin Pharmaceuticals CEOs

Here are other CEOs of BioMarin Pharmaceuticals

Jean-Jacques Bienaimé

Ex-CEO of BioMarin Pharmaceuticals

May 2005 - November 2023